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compound heterozygous POLG mutations. Speciﬁc POLG2 and TK2 mutations did not delay mtDNA
repopulation rates. These observations are consistent with the hypothesis that mutations in POLG impair
mtDNA repopulation within intact cells, and provide a potential method of demonstrating the functional
consequences of putative pathogenic alleles causing a defect of mtDNA synthesis.s, Central Parkway, Newcastle
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Mitochondria contain multiple copies of mitochondrial DNA
(mtDNA), which codes for 13 essential components of the mitochon-
drial respiratory chain which are essential for aerobic metabolism in
all nucleated mammalian cells. The efﬁcient synthesis of adenosine
triphosphate (ATP) is critically dependent on the amount and quality
of mtDNA within single cells. Pathogenic mutations of mtDNA can
affect the structure of respiratory chain subunits, or affect the intra-
mitochondrial protein synthetic machinery. Likewise, a drastic
reduction in mtDNA levels also leads to a decrease in intra-
mitochondrial protein synthesis, compromising cellular function
through a relative deﬁciency of available ATP. Unlike nuclear DNA,
mitochondrial DNA (mtDNA) is continually copied and degraded,
independent of the cell cycle (so called “relaxed replication”) [1]. This
means that any disruption of the mtDNA replication machinery can
have almost immediate effects on cellular function.
Nuclear gene mutations causing secondary defects of mitochon-
drial DNA (mtDNA) are amajor cause of human genetic disease [2]. An
overlapping spectrum of dominantly-inherited neuromuscular phe-
notypes have been described in families transmitting mutations in
POLG and POLG2 [3,4], PEO1 [5], ANT1 [6], and OPA1 [7]. These genescode for proteins that are intimately involved in mtDNA synthesis
(reviewed comprehensively in [8]). POLG codes for polγ, the only DNA
polymerase within mitochondria. POLG2 codes for the accessory (or
p55) subunit of polγ, which binds to the linker region of the catalytic
subunit and promotes processivity during mtDNA synthesis. PEO1
codes for themtDNAhelicase Twinkle, and ANT1 codes for the adenine
nucleotide translocase, which maintains intra-mitochondrial nucleo-
side levels. OPA1 codes for the mitochondrial fusion–ﬁssion protein
Opa1, which also plays a role in apoptosis. Mutations in the genes
encoding these proteins lead to secondary mtDNA mutations which
accumulate in post-mitotic tissues and cause progressive multisystem
neurological disease. The mtDNA mutations affect the synthesis or
structure of respiratory chain proteins, leading to a biochemical defect
of oxidative phosphorylation and a deﬁciency of ATP synthesis [9,10].
On the other hand, recessive mutations in POLG and PEO1 also cause a
loss of mtDNA (depletion) and a more severe childhood disorder with
encephalopathy and liver failure, including the Alpers-Huttenlocher
syndrome (AHS) [11,12]. Several other recessive mtDNA depletion
syndromes have been described [2], many due to mutations affecting
proteins that regulate intra-mitochondrial nucleoside levels, such as
TK2 encoding thymidine kinase 2 [13]. The loss of mtDNA also leads to
a decrease in intra-mitochondrial protein synthesis, which compro-
mises oxidative phosphorylation and leads to a decrease in ATP
synthesis [14].
POLG remains the major identiﬁed cause of autosomal mitochon-
drial disease, with an exponential growth in the number of new POLG
substitutions identiﬁed in patients with secondary mtDNA defects.
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population, and there have been several cases where putative
pathogenic alleles were later described in control subjects. Proving
the pathogenic nature of novel POLG mutations is a major challenge
facing the ﬁeld. Several groups have established an in vitro method of
studying the biochemical consequences of different alleles by
isolating recombinant proteins over-expressed in baculovirus-
infected cells [2]. Although this has shown that several potentially
pathogenic alleles compromise catalytic activity, proof-reading and
processivity of the enzyme [2], technical limitations restrict this
approach to speciﬁc regions of the protein, excluding some known
and putative pathogenic alleles from analysis. In addition, the in vitro
approaches to measuremtDNA replication are not all applicable when
studying the potential effects of additional proteins that affect intra-
mitochondrial nucleotide pools, or proteins thought to interact with
the mtDNA replisome [15]. An alternative approach involves the
measurement of polγ activity in cell extracts [16]. Although this
enables the evaluation of the intact enzyme, even with the optimal
enrichment through mitochondrial fractionation, there is inevitable
contamination with nuclear DNA polymerase and RNase activity,
limiting the sensitivity of the assay for mildly deleterious POLG
mutations. To address these issues we developed a simple kinetic
assay for mtDNA replication in intact primary human cells by
depleting cell lines of mtDNA by treatment with ethidium bromide
(EtBr) and comparing the rate of repopulation in patient cell lines to
controls. Ethidium bromide is a known inhibitor of mitochondrial
transcription and replication processes but with no effect on nuclear
DNA [17,18]. This double stranded DNA intercalating drug has
effectively been used to reduce the copy number of mtDNA in
proliferating cells [19]. The effect of the drug is reversible; so that once
EtBr is removed from the culture media, cells are able to repopulate
their mtDNA [20]. This approach has been used to investigate the
mechanisms regulating mtDNA copy number within cells [18,21]. It
has also been used to show that deleted smaller mtDNA molecules
repopulate cells faster thanwild-typemolecules [22]. Here we applied
a similar approach to cell lines with a genetically determined mtDNA
replication defect for the ﬁrst time.
2. Methods
Primary human ﬁbroblasts were cultured from seven patients
available to us in our laboratories (P1–P7) and seven healthy control
subjects (C1–C7). Patients 1, 4, and 5 (P1, P4, and P5) had AHS caused
by compound heterozygous mutations in POLG P1:p.W748S and p.
G848S; P4: p.W748S and c.3600delT; and P5: p.G737R and p.A767N
[23,24] with mtDNA depletion in liver and/or muscle. Patients 2 and 3
(P2, P3) had AHS caused by homozygous mutations in POLG P2:p.
R1096C; and P3:homozygous p.T251I, p587L. Patient 6 (P6) had a
recessive mitochondrial DNA depletion myopathy due to a homozy-
gous deletion of exons 1 and 2 of TK2:−270+2561del-ins; 7287–
7335inv, with mtDNA depletion in the skeletal muscle. Patient 7 (P7)
had autosomal dominant chronic progressive external ophthalmo-
plegia due to a heterozygous POLG2 substitution (c.1352GNA/p.
G451E) with multiple mtDNA deletions in the skeletal muscle [4].
Clinical descriptions of patients 1, 4, 5 and 7 have been published
previously [3,15,16], but the clinical features of patients 2, 3, and 6
have not been described before.
Patient 2 was a one-year-old boy of Arabic ethnic origin, having
ﬁrst grade cousins as parents. He suffered from multifocal therapy-
refractory epilepsy. At the age of one year and three months MRI
showed a global supratentorial reduction of brain volume with a
discrete signal-increased hippocampus in the FLAIR sequence, which
was interpreted as a probable right-sided hippocampal sclerosis.
Skeletal muscle biopsy was taken at the age of one year. In the biopsy
COX-negative ﬁbers, reduced mtDNA copy number (863+/−101) in
contrast to controls (16045+/−8817), and multiple deletions weredetected. Genetic characterization showed the homozygous R1096C
mutation in POLG1.
Patient 3 was a 26-year-old woman, whose symptoms ﬁrst
appeared at age 16 as mainly nocturnal nausea followed by loss of
consciousness without motor relinquishing (no tongue bite). In ten
years eight attacks were reported since the ﬁrst seizure. These were
triggered by stress, but she could prevent the loss of consciousness by
learned strategies in two cases. Furthermore obsessive–compulsive
disorder was diagnosed at the age of 24 and she was treated in the
psychiatry. The electroencephalogram (EEG) at this time showed
fronto-temporal-parietal accented deceleration. Clear spike-wave and
sharp-wave could not be ascertained. EEG a year before showed
repeated high-tension potentials in theta band bifrontally. Genetic
characterization showed a pathogenic homozygous T251I/P587L
mutation combination in POLG1.
Patient 6 was a 2-month-old boy. His Turkish parents are second
grade consanguineous, without any known familiar disorders. The
baby was prematurely delivered at the 36+2 week of pregnancy.
Fetal hypokinesia with dysmorphic signs at a normal fetal karyotype
(46XY) were noted. Further features included: lissencephaly/pachy-
gyria, microecephaly, bilateral optic atrophy, severe peripartal
asphyxia, respiratory insufﬁciency, arterial hypotonia, low T3/T4
syndrome, anemia, electrolytic dysfunction, thrombosis, capillary-
leak syndrome, bilateral chylothorax, and occipital skin necrosis. EEG
at the second day of life was extremely low-strained, no epileptic
activity was detected. Skeletal muscle biopsy by the age of one month
revealed ﬁber atrophy, ﬁber destruction and almost complete COX-
deﬁciency. MtDNA copy number in skeletal muscle was reduced to
92 +/−6 (controls: 16045+/−8817). Genetic characterization
showed a homozygous mutation in TK2 (−270+2561del-ins;
7287–7335inv). At the age of 56 days the baby died from multi-
organ dysfunction.
Cells were grown in MEM Earles media (GIBCO) supplemented
with 10% fetal bovine serum, 0.1 mg/ml sodium pyruvate, 2 mM L-
glutamine and 0.05 mg/ml uridine. All cells were grown in a
humidiﬁed atmosphere with 5% CO2 at 37 °C. MtDNA depletion was
induced by the addition of 50 ng/ml ethidium bromide (EtBr) to the
culture medium for either 7 days (experiment 1) or 16 days
(experiment 2) before a return to normal media. Untreated cell
lines were studied in parallel, and all cells were kept between 50 and
80% conﬂuence with excess fresh medium to ensure exponential
growth. We did not observe differences in the cell doubling times
between the patient and control cell lines during ethidium bromide
treatment, nor during the repopulation phase of the experiment. All
cell culture studies were done in three independent experiments.
The amount of mtDNA in the patient P4, P5, P7 and control C3–C7
ﬁbroblasts was measured in duplicate by real-time PCR using iQ™
Sybr Green on the BioRad ICycler (BioRad, CA) to a target template
spanning from nt3459 to nt3569 of the MTND1 gene as described
[25,26], normalized using a nuclear-encoded template for the beta
microglobulin (B2M) gene spanning from nucleotide 4146 to
nucleotide 4376 (NCBI, AC025270). Relative copy number was
calculated from the threshold cycle value, ΔCt value, where the
mean amount of mtDNA/cell=2(2–ΔCt), to account for the two copies
of B2M. The percentage difference in the mtDNA copy number for the
untreated and treated arms of the study were compared on each
analysis day.
MtDNA copy numbers in patient P1–P3, P6 and control C1-C2
ﬁbroblasts were determined using the primers MT16520F and MT35R
used together with probe MT16557TM to detect mitochondrial DNA
[24]. Nuclear DNA content was estimated by amplifying a fragment
from the single-copy gene Kir4.1 with primers KIR835F and KIR903R
in the presence of probe KIR857TM. The quantitative PCR was
performed on the MyiQ Real-Time PCR System (Bio-Rad, Munich,
Germany). The exact cycle number values were calculated as ln(c)/b,
which corresponds to the inﬂection point of non-linear ﬁtted
Fig. 1.MtDNA depletion and repopulation in control human ﬁbroblasts and ﬁbroblasts
from three POLG patients and a TK2 patient after 7 days of treatment with 50 ng/ml
ethidium bromide. (A) Controls C1 & C2 (B) Patient P1:p.W748S and p.G848S in POLG;
P2:p.R1096C/p.R1096C in POLG; P3:p.T251I, p587L/p.T251I, p587L in POLG. (C) Patient
6 (P6): homozygous deletion of exons 1 and 2 of TK2 −270+2561del-ins; 7287–
7335inv. Data points show the mean of three independent experiments +/−SD values.
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following equation: y=y0+a (1−e–bx)c (y0, background ﬂuores-
cence intensity; y, measured ﬂuorescence intensity; x, cycle number;
and a, b, c, curve parameters to be ﬁtted). Calculations were
performed using the SigmaPlot 2001 statistical analysis software.
For each value three independent experiments were carried out with
different concentrations of template DNA, each experiment in
triplicates, and primer efﬁciencies were calculated.
For patients P4, P5, P7 and control C3–C7 ﬁbroblasts multiple
mtDNA deletions were investigated using a long range polymerase
chain reaction (PCR) assay which ampliﬁes a ~10 kb fragment across
the major arc of mtDNA genome using a pair of primers (L6249
(nucleotides 6249–6265) and H16215 (nucleotides 16225–16196)).
The potential presence of large mitochondrial DNA deletions was
investigated for patient P1–P3, P6 and control C1-C2 ﬁbroblasts by
amplifying overlapping PCR products of 9.5–12.7 kb size using a
JumpStart AccuTaq DNA polymerase (Sigma-Aldrich, Steinheim,
Germany) and the following primer pairs: MT2623F with
MT14695R, MT3922F with MT45R, MT16520F with MT10673R,
MT5462F with MT16084R, and MT7027F with MT45R. The mtDNA
deletion was quantiﬁed by a modiﬁed version of the single-molecule
PCR method [27]. Primers MT3922F and MT45R were used in 42
cycles of the previously described long PCR program to amplify a 12.7-
kb-long part of the mitochondrial genome. DNA samples were diluted
to a degree such that after ampliﬁcation, in addition to the long wild-
type product, only 1 or 2 deletion speciﬁc (i.e. shorter) or no products
were detectable in each lane. We assume that under these
circumstances, each deletion-speciﬁc band is derived from a single
deleted mtDNA molecule. Deletion-speciﬁc bands were then counted
in all lanes, and this number was compared with total mtDNA copy
numbers determined in a similar manner but using a higher dilution
of the DNA sample (i.e. on average, less than 1 copy of mtDNA per
reaction). In the latter reaction, a primer pair (primers MT16520F and
MT1144R) was used that spanned the D-loop region and part of the
small arc that are very rarely deleted. This gave an ampliﬁcation
product from all types of mtDNA molecules irrespective of whether
they were deleted.
3. Results
The absolute amount of mtDNA in the untreated ﬁbroblasts from
four of the POLG patients was signiﬁcantly less than in the controls
(P1, P=1.75×10−9; P2, P=2.27×10−8; P3, P=5.83×10−6; and P5,
P=0.028), but no different to controls for one POLG patient (P4), and
no different to controls for the POLG2 and TK2 patients. There was no
signiﬁcant change in the level of mtDNA in untreated ﬁbroblasts from
patients and controls (C1–C7 and P1–P7) when these were cultured
through multiple passages in parallel with the treated cells (Supple-
mentary Table 1). Treatment with EtBr caused signiﬁcant depletion of
mtDNA in control and patient cell lines. Both control and patient
ﬁbroblasts developed mtDNA depletion at the same rate, falling to
b15% of the untreated steady state within 10 days exposure. After
removal of the EtBr on day 7, the mtDNA copy number increased to
pre-treatment levels, reaching normal levels within 10 days in control
cell lines and in the cell line of the TK2 patient (Fig.1A, B and C and
Supplementary Table 2a). ThemtDNA content for the POLG ﬁbroblasts
was signiﬁcantly less than the controls at all time points in patients P2
and P3, but patient P1 returned to normal levels 12 days after
withdrawal of EtBr (Fig. 1B). By contrast, the ﬁbroblasts from the
patient with a homozygous deletion of two TK2 exons (P6) showed
repopulation proﬁles faster than that observed in the controls
(Fig. 1C). We therefore carried out further experiments with a longer
period of exposure to EtBr in order to demonstrate more dramatic
effects in ﬁbroblasts with POLG mutations.
The remaining patient (P4, P5, and P7) and control cell lines (C3–
C7) were treated with EtBr for 16 days (Fig. 2). As before, both patientand control cell lines developed the mtDNA depletion at the same rate
(Fig. 2A, B and C and Supplementary Table 2b). The control cell lines
exposed to EtBr for 16 days showed a similar rate of repopulation to
control cell lines exposed to EtBr for 7 days (Figs. 1A and 2A). By
contrast, the three patient ﬁbroblast cell lines showed different rates
of repopulation with mtDNA. MtDNA levels in ﬁbroblasts from the
two POLG patients (P4 and P5) never reached pre-treatment levels
29 days after removal of EtBr (P4=28.1%±19.4, P=0.034 compared
to the controls, P5=7.87%±7.13, P=0.003 compared to the controls;
Fig. 2B). By contrast, ﬁbroblasts from the patient with a heterozygous
POLG2 substitution (P7) showed repopulation proﬁles similar to that
observed in the controls at all time points (Fig. 2C). To conﬁrm our
ﬁndings, we repeated the entire experiment for one cell line (P4) and
obtained identical results (Fig. 2D).
No rearrangements of mtDNA were detected in the treated or
untreated cell ﬁbroblasts from the controls and from P2-P7. In the
Fig. 2. MtDNA depletion and repopulation in control human ﬁbroblasts and patients with a mtDNA maintenance disorder after 16 days of treatment with 50 ng/ml ethidium
bromide. (A) Controls C3–C7. (B) Patients P5: p.G737R and p.A767N in POLG; P4: p.w748S and c.3600delT in POLG. (C) P7: c.1352 GNA/p.G451E in POLG2. (D) Reproducibility data
for Patient P4: p.W748S and c.3600delT in POLG. Data points show the mean of three independent experiments +/−SD values.
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an inverted insertion 7395–9299 was detected, both in the untreated
and the EtBr treated cells. The proportion of deleted mtDNA did not
change during or after treatment with EtBr (Fig. 3). The percentage
level of mutatedmtDNA before EtBr treatmentwas 0.37%±0.03%. The
percentage level of mutated mtDNA immediately after EtBr treatment
was 1.44±0.09%. The percentage level of mutated mtDNA after
repopulation was 0.20±0.02%.
4. Discussion
Here we show that speciﬁc POLG mutations can delay the rate of
repopulation of mtDNA in human ﬁbroblasts exposed to EtBr. Given
that we did not observe any difference between control and patient
cell doubling times before or after EtBr treatment, these ﬁndings are
consistent with the notion that pathogenic POLG mutations can
directly inﬂuence mtDNAmaintenance within intact human cells, and
are in keeping with in vitro data showing reduced catalytic activity
and processivity for several pathogenic POLG alleles [2].
Intriguingly, the steady-state level of mtDNA in untreated
ﬁbroblasts from one POLG patient (P4) was no different to controls.Fig. 3. Percentage level of deleted mtDNA before, during and after EtBr treatment in
patient 1. Long range PCR products were separated on an agarose gel. Uppermost bands
represent non-deleted mitochondrial genomes (WT); lower bands show the presence
of shorter DNA molecules with deletions (DEL). Lanes: 1—marker; 2, 3—after
repopulation; 4, 5—before EtBr treatment; 6, 7—after EtBr treatment; and 8—undeleted
control.This has been observed before [28], and suggests that the capacity for
adequatemtDNA turnover in quiescentﬁbroblasts is not compromised
by some pathogenic POLG alleles. However, in contrast to the previous
study, where depletion was only observed in cells harbouring two
mutations affecting either the polymerase or exonuclease catalytic
domain [28], we also observed depletion in one patient (P5) with two
linker-regionmutations (p.G737R and p.A767N). This provides further
evidence of the crucial role played by the linker region in mtDNA
replication, probably through the direct interaction with the p55
accessory subunit which promotes processive polymerase activity [4].
Notably, EtBr caused the loss of mtDNA at remarkably similar rates
in patient and control ﬁbroblast cell lines. This suggests that 50 ng/ml
EtBr effectively terminates mtDNA synthesis, and the loss of mtDNA
during EtBr exposure is likely to be due to the natural destruction of
mtDNA as part of the mtDNA turnover during relaxed replication. By
inference, in the steady state, this must be matched by equivalent
rates of mtDNA synthesis to maintain the constant amount of mtDNA
we observed in the untreated cells. Thus, if mtDNA replication is
suddenly abolished by EtBr treatment, then the loss of mtDNA will
occur through the same endogenous destruction mechanism that
occurs in the steady state. In this context, the rate of mtDNA depletion
during EtBr exposure will provide one estimate of the steady-state
turnover of mtDNA by relaxed replication. The time course we
observed is in keeping with previous measurements of mtDNA
turnover using a different approach [29,30].
Since the steady state mtDNA content of a cell is determined by the
balance between replication and degradation, it would be reasonable
to expect a cell to compensate for the mtDNA replication defect by
slowing down mtDNA degradation. However, the same rates of
ethidium-bromide induced mtDNA depletion that we observed in
patient and control cell lines suggest that the presence of POLG, POLG2,
and TK2mutations does not lead to a slower degradation of mtDNA in
an attempt to compensate for the mtDNA maintenance defect. The
cellular mtDNA content therefore is likely to be regulated solely
through the mechanism controlling mtDNA replication.
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the individual cell lines were less consistent. This may reﬂect differences
in the dynamics of cell proliferation between different sub-clones, cell–
cell mosaicism in mtDNA levels previously observed in POLG ﬁbroblasts
[28], or it may reﬂect differences in mtDNA replication rates at different
stages of the cell cycle [31]. Despite this variation, we observed clear
differences between mutated POLG ﬁbroblasts, and ﬁbroblasts with the
heterozygous POLG2 and homozygous TK2mutations, although thismust
be interpretedwith caution because we only studied one cell line in each
case. Given that the same POLG2 mutation (c.1352GNA/p.G451E)
compromised polymerase activity through impaired subunit interaction
in the recombinant in vitro system [4], it seems unlikely that the absence
of a repopulation defect in ﬁbroblasts reﬂects the non-pathogenic nature
of this allele. It is possible, that the defect caused by a heterozygous POLG2
mutation is more subtle compared to the compound heterozygous POLG
cell lines. Alternatively, the normal rates of repopulation could either
reﬂect the relative insensitivity of the assay we present here, or be due to
compensatorymechanismswithin the intact organelle that arenot at play
in the in vitro assay, which is based on short strands of mtDNA synthesis
using limited components of the replisome under idealized experimental
conditions [4]. The absence of an effect of the TK2 mutations on mtDNA
repopulation rates inﬁbroblasts is inkeepingwith thewell-knowntissue-
speciﬁcity of this particular mtDNA depletion disorder, where the major
phenotype is limited to skeletal muscle. Tissue-speciﬁc compensatory
mechanisms inﬁbroblasts probably stabilise themitochondrial dTTPpool,
as recently reported in ﬁbroblasts from two patients with different
deleterious TK2mutations [32]. These mechanisms could account for the
rapid repopulation and supra-normal mtDNA levels seen N5 days after
the withdrawal of EtBr (Fig. 1C). Further work will clarify the extent and
magnitude of these effects for the rangeof differentmutations in different
genes known to be involved in mtDNA maintenance, and the sensitivity
and speciﬁcity of the repopulation assay.
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